IT201800009731A1 - Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante - Google Patents
Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante Download PDFInfo
- Publication number
- IT201800009731A1 IT201800009731A1 IT102018000009731A IT201800009731A IT201800009731A1 IT 201800009731 A1 IT201800009731 A1 IT 201800009731A1 IT 102018000009731 A IT102018000009731 A IT 102018000009731A IT 201800009731 A IT201800009731 A IT 201800009731A IT 201800009731 A1 IT201800009731 A1 IT 201800009731A1
- Authority
- IT
- Italy
- Prior art keywords
- treatment
- pharmaceutical composition
- paclitaxel
- prodrug
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| LTEPPCT/IB2019/059073T LT3870233T (lt) | 2018-10-25 | 2019-10-23 | Paklitakselio ir hialurono rūgšties konjugatas, skirtas į raumenis neplintančio šlapimo pūslės vėžio gydymui |
| EP19801630.5A EP3870233B1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| HUE19801630A HUE066288T2 (hu) | 2018-10-25 | 2019-10-23 | Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében |
| PL19801630.5T PL3870233T3 (pl) | 2018-10-25 | 2019-10-23 | Koniugat paklitakselu z kwasem hialuronowym do leczenia raka pęcherza moczowego nienaciekającego mięśniówki |
| CN201980064603.9A CN112805035A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
| SM20240021T SMT202400021T1 (it) | 2018-10-25 | 2019-10-23 | Coniugato paclitaxel-acido ialuronico nel trattamento del carcinoma vescicale non muscolo-invasivo |
| KR1020217007729A KR102913965B1 (ko) | 2018-10-25 | 2019-10-23 | 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체 |
| MA63879A MA63879B1 (fr) | 2018-10-25 | 2019-10-23 | Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle |
| FIEP19801630.5T FI3870233T3 (fi) | 2018-10-25 | 2019-10-23 | Paklitakseli-Hyaluronihapon konjugaatti käytettäväksi ei-lihasinvasiivisen virtsarakon syövän hoidossa |
| CN202510138513.7A CN119792555A (zh) | 2018-10-25 | 2019-10-23 | 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物 |
| PT198016305T PT3870233T (pt) | 2018-10-25 | 2019-10-23 | Conjugado de paclitaxel-ácido hialurónico no tratamento de cancro da bexiga não-músculo invasivo |
| DK19801630.5T DK3870233T3 (da) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronsyrekonjugat til behandlingen af ikke-muskelinvasiv blærekræft |
| JP2021515655A JP7518815B2 (ja) | 2018-10-25 | 2019-10-23 | 筋層非浸潤性膀胱がんの治療におけるパクリタキセル－ヒアルロン酸複合体 |
| EA202190614A EA202190614A1 (ru) | 2018-10-25 | 2019-10-23 | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря |
| CA3112188A CA3112188A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| SI201831054T SI3870233T1 (sl) | 2018-10-25 | 2019-10-23 | Konjugat paklitaksel-hialuronske kisline za zdravljenje nemišično invazivnega raka mehurja |
| HRP20240188TT HRP20240188T1 (hr) | 2018-10-25 | 2019-10-23 | Konjugat paklitaksel-hijaluronska kiselina u liječenju nemišićno invazivnog raka mjehura |
| US16/959,979 US20200397909A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| RS20240122A RS65193B1 (sr) | 2018-10-25 | 2019-10-23 | Konjugat paklitaksel-hijaluronska kiselina u lečenju nemišićno invazivnog kancera bešike |
| PCT/IB2019/059073 WO2020084525A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| ES19801630T ES2971217T3 (es) | 2018-10-25 | 2019-10-23 | Conjugado de paclitaxel-ácido hialurónico en el tratamiento del cáncer de vejiga no músculo invasivo |
| US17/204,183 US20210196833A1 (en) | 2018-10-25 | 2021-03-17 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| US17/315,962 US12465649B2 (en) | 2018-10-25 | 2021-05-10 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| US18/539,827 US20240123077A1 (en) | 2018-10-25 | 2023-12-14 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201800009731A1 true IT201800009731A1 (it) | 2020-04-25 |
Family
ID=65324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (enExample) |
| EP (1) | EP3870233B1 (enExample) |
| JP (1) | JP7518815B2 (enExample) |
| KR (1) | KR102913965B1 (enExample) |
| CN (2) | CN119792555A (enExample) |
| CA (1) | CA3112188A1 (enExample) |
| DK (1) | DK3870233T3 (enExample) |
| EA (1) | EA202190614A1 (enExample) |
| ES (1) | ES2971217T3 (enExample) |
| FI (1) | FI3870233T3 (enExample) |
| HR (1) | HRP20240188T1 (enExample) |
| HU (1) | HUE066288T2 (enExample) |
| IT (1) | IT201800009731A1 (enExample) |
| LT (1) | LT3870233T (enExample) |
| MA (1) | MA63879B1 (enExample) |
| PL (1) | PL3870233T3 (enExample) |
| PT (1) | PT3870233T (enExample) |
| RS (1) | RS65193B1 (enExample) |
| SI (1) | SI3870233T1 (enExample) |
| SM (1) | SMT202400021T1 (enExample) |
| WO (1) | WO2020084525A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) * | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138572A2 (en) | 1983-10-11 | 1985-04-24 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
| EP0716688A1 (en) | 1993-07-30 | 1996-06-19 | Fidia Advanced Biopolymers S.R.L. | Process for the preparation and purification of high molecular weight hyaluronic acid |
| WO2004035629A2 (en) * | 2002-10-18 | 2004-04-29 | Fidia Farmaceutici S.P.A. | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| EP2614088A1 (en) | 2010-09-09 | 2013-07-17 | Fidia Farmaceutici S.p.A. | Process for the production of hyaluronic acid in escherichia coli or bacillus subtilis |
| EP2614087A1 (en) | 2010-09-09 | 2013-07-17 | Fidia Farmaceutici S.p.A. | Process for the production of hyaluronic acid in escherichia coli or bacillus megaterium |
| WO2018020458A1 (en) | 2016-07-28 | 2018-02-01 | Fidia Farmaceutici S.P.A. | Process for the preparation and purification of the sodium salt of hyaluronic acid |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| AR047938A1 (es) * | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| ES2653679T3 (es) | 2011-11-09 | 2018-02-08 | Spinalcyte, Llc | Fibroblastos dérmicos para el tratamiento de enfermedad discal degenerativa |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/en active Active
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 CA CA3112188A patent/CA3112188A1/en active Pending
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/en not_active Ceased
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138572A2 (en) | 1983-10-11 | 1985-04-24 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
| EP0716688A1 (en) | 1993-07-30 | 1996-06-19 | Fidia Advanced Biopolymers S.R.L. | Process for the preparation and purification of high molecular weight hyaluronic acid |
| WO2004035629A2 (en) * | 2002-10-18 | 2004-04-29 | Fidia Farmaceutici S.P.A. | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| EP2045270A2 (en) | 2002-10-18 | 2009-04-08 | FIDIA FARMACEUTICI S.p.A. | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| EP2614088A1 (en) | 2010-09-09 | 2013-07-17 | Fidia Farmaceutici S.p.A. | Process for the production of hyaluronic acid in escherichia coli or bacillus subtilis |
| EP2614087A1 (en) | 2010-09-09 | 2013-07-17 | Fidia Farmaceutici S.p.A. | Process for the production of hyaluronic acid in escherichia coli or bacillus megaterium |
| WO2018020458A1 (en) | 2016-07-28 | 2018-02-01 | Fidia Farmaceutici S.P.A. | Process for the preparation and purification of the sodium salt of hyaluronic acid |
Non-Patent Citations (9)
| Title |
|---|
| BASSI P F ET AL: "Paclitaxel-Hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Guerin Refractory Carcinoma In Situ of the Bladder: Results of a Phase I Study", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 185, no. 2, 1 February 2011 (2011-02-01), pages 445 - 449, XP027595068, ISSN: 0022-5347, [retrieved on 20110109], DOI: 10.1016/J.JURO.2010.09.073 * |
| HUIZING MT ET AL., CANCER INV, vol. 13, 1995, pages 381 - 404 |
| ISABELLA MONIA MONTAGNER ET AL: "Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines", UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS, vol. 31, no. 7, 1 October 2013 (2013-10-01), AMSTERDAM, NL, pages 1261 - 1269, XP055414808, ISSN: 1078-1439, DOI: 10.1016/j.urolonc.2012.01.005 * |
| LUO ET AL., BIOMACROMOLECULES, vol. 1, no. 2, 2000, pages 208 - 218 |
| MANFREDI JJ ET AL., J CELL BIOL, vol. 94, 1982, pages 688 - 696 |
| MONICA CAMPISI ET AL: "ONCOFID(TM)-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis", CURRENT BIOACTIVE COMPOUNDS, vol. 7, no. 1, 1 March 2011 (2011-03-01), pages 27 - 32, XP055599334, ISSN: 1573-4072, DOI: 10.2174/157340711795163848 * |
| NUIJEN B ET AL., INVESTIGATIONAL NEW DRUGS, vol. 19, 2001, pages 143 - 153 |
| ROSATO A ET AL: "HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer", UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 3, 1 May 2006 (2006-05-01), pages 207 - 215, XP028071920, ISSN: 1078-1439, [retrieved on 20060501], DOI: 10.1016/J.UROLONC.2005.08.020 * |
| TERBOJEVICH ET AL., CARBOHYDR RES, 1986, pages 363 - 377 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2971217T3 (es) | 2024-06-04 |
| KR102913965B1 (ko) | 2026-01-16 |
| JP2022503771A (ja) | 2022-01-12 |
| EP3870233B1 (en) | 2023-12-06 |
| FI3870233T3 (fi) | 2024-02-07 |
| LT3870233T (lt) | 2024-02-26 |
| SMT202400021T1 (it) | 2024-03-13 |
| PT3870233T (pt) | 2024-02-01 |
| DK3870233T3 (da) | 2024-02-05 |
| JP7518815B2 (ja) | 2024-07-18 |
| US20240123077A1 (en) | 2024-04-18 |
| CN119792555A (zh) | 2025-04-11 |
| EA202190614A1 (ru) | 2021-06-03 |
| PL3870233T3 (pl) | 2024-05-06 |
| CA3112188A1 (en) | 2020-04-30 |
| US20210268119A1 (en) | 2021-09-02 |
| KR20210083249A (ko) | 2021-07-06 |
| US12465649B2 (en) | 2025-11-11 |
| EP3870233A1 (en) | 2021-09-01 |
| HRP20240188T1 (hr) | 2024-05-10 |
| CN112805035A (zh) | 2021-05-14 |
| HUE066288T2 (hu) | 2024-07-28 |
| RS65193B1 (sr) | 2024-03-29 |
| WO2020084525A1 (en) | 2020-04-30 |
| SI3870233T1 (sl) | 2024-03-29 |
| MA63879B1 (fr) | 2024-02-29 |
| US20200397909A1 (en) | 2020-12-24 |
| US20210196833A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goodarzi et al. | CD 44‐targeted docetaxel conjugate for cancer cells and cancer stem‐like cells: a novel hyaluronic acid‐based drug delivery system | |
| Qian et al. | A paclitaxel‐based mucoadhesive nanogel with multivalent interactions for cervical cancer therapy | |
| Xiong et al. | Peptide–Gold Nanoparticle Hybrids as Promising Anti‐Inflammatory Nanotherapeutics for Acute Lung Injury: In Vivo Efficacy, Biodistribution, and Clearance | |
| EP2279006B1 (en) | Therapeutic use of pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias | |
| US20240123077A1 (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| Haider et al. | Thermogelling platform for baicalin delivery for versatile biomedical applications | |
| Qiu et al. | Hyaluronic acid-conjugated fluorescent probe-shielded polydopamine nanomedicines for targeted imaging and chemotherapy of bladder cancer | |
| Cho et al. | Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth | |
| CA2911906A1 (en) | Therapeutic and imaging compositions and uses thereof | |
| Lin et al. | Enhancing targeted photodynamic therapy: star-shaped glycopolymeric photosensitizers for improved selectivity and efficacy | |
| Zhao et al. | ROS/pH dual-responsive quercetin-loaded guanosine borate supramolecular hydrogel enema in dextran sulfate sodium-induced colitis in mice | |
| Tong et al. | Amplifying ER Stress via Biodegradable Pseudo‐Conjugated Polymer Nanoparticles for Enhanced Sonodynamic Immunotherapy | |
| Patel et al. | Dual stimuli-responsive gemcitabine-conjugated alginate-chitosan nanoparticles for triple-negative breast cancer therapy: A smart approach | |
| Sonvico et al. | Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma | |
| CN104398504B (zh) | 一种去氧鬼臼毒素类药物的药物组合物及其制备方法和制剂 | |
| Zhang et al. | Poly (photosensitizer-prodrug) unimolecular micelles for chemo-photodynamic synergistic therapy of antitumor and antibacteria | |
| IT201900019762A1 (it) | Composizione farmaceutica per uso nel trattamento della cistite di varia eziologia | |
| HK40048954A (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| HK40048954B (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| EA043782B1 (ru) | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря | |
| Ding et al. | Glycolysis inhibition via pH-responsive nanoparticles modulates macrophage reprogramming for sepsis immunotherapy | |
| Kikani et al. | Design and Synthesis of an Aggregation-Induced Emission-Active Quad-Functional “Curcumin-Spiced Marvel” for Engineering of Sialic Acid-Targeted Nanoplatform for Cancer Therapy | |
| US20170216343A1 (en) | Viscosupplement composition comprising ulvan for treating arthritis | |
| Zhu | Nanoparticles Targeting Tumour Associated Macrophages | |
| Shi et al. | Enhanced pharmacokinetic and therapeutic of GSH-responsive mPEG-b-P (HPMA)-SGI1776 conjugate for osteosarcoma |